FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Hartig

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Anatomy

Cell Line

Procedures

Disorders

Anxiety Disorders

Co-author Network

Publications

TOP 3
Paul J Gilligan; Liqi He; Todd Clarke; Parcharee Tivitmahaisoon; Snjezana Lelas; Yu-Wen Li; Karen Heman; Lawrence Fitzgerald; Keith Miller; Ge Zhang; Anne Marshall; Carol Krause; John F McElroy; Kathyrn Ward; Helen Shen; Harvey Wong; Scott Grossman; Gregory Nemeth; Robert Zaczek; Stephen P Arneric; Paul R Hartig; David W Robertson; George Trainor
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
Paul J Gilligan; Todd Clarke; Liqi He; Snjezana Lelas; Yu-Wen Li; Karen Heman; Lawrence Fitzgerald; Keith Miller; Ge Zhang; Anne Marshall; Carol Krause; John F McElroy; Kathyrn Ward; Kim Zeller; Harvey Wong; Steven Bai; Joanne Saye; Scott Grossman; Robert Zaczek; Stephen P Arneric; Paul R Hartig; David Robertson; George Trainor
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Snjezana Lelas; Harvey Wong; Yu-Wen Li; Karen L Heman; Kathryn A Ward; Kim L Zeller; Kristine K Sieracki; Joseph L Polino; Helen E Godonis; Shelly X Ren; Xiao-Xin Yan; Stephen P Arneric; David W Robertson; Paul R Hartig; Scott Grossman; George L Trainor; Rebecca A Taub; Robert Zaczek; Paul J Gilligan; John F McElroy
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Hartig (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Paul J Gilligan; Liqi He; Todd Clarke; Parcharee Tivitmahaisoon; Snjezana Lelas; Yu-Wen Li; Karen Heman; Lawrence Fitzgerald; Keith Miller; Ge Zhang; Anne Marshall; Carol Krause; John F McElroy; Kathyrn Ward; Helen Shen; Harvey Wong; Scott Grossman; Gregory Nemeth; Robert Zaczek; Stephen P Arneric; Paul R Hartig; David W Robertson; George Trainor
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
Journal of medicinal chemistry 2009;52(9):3073-83.
2009: Paul J Gilligan; Todd Clarke; Liqi He; Snjezana Lelas; Yu-Wen Li; Karen Heman; Lawrence Fitzgerald; Keith Miller; Ge Zhang; Anne Marshall; Carol Krause; John F McElroy; Kathyrn Ward; Kim Zeller; Harvey Wong; Steven Bai; Joanne Saye; Scott Grossman; Robert Zaczek; Stephen P Arneric; Paul R Hartig; David Robertson; George Trainor
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Journal of medicinal chemistry 2009;52(9):3084-92.
2004: Snjezana Lelas; Harvey Wong; Yu-Wen Li; Karen L Heman; Kathryn A Ward; Kim L Zeller; Kristine K Sieracki; Joseph L Polino; Helen E Godonis; Shelly X Ren; Xiao-Xin Yan; Stephen P Arneric; David W Robertson; Paul R Hartig; Scott Grossman; George L Trainor; Rebecca A Taub; Robert Zaczek; Paul J Gilligan; John F McElroy
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
The Journal of pharmacology and experimental therapeutics 2004;309(1):293-302.
2003: Argyrios G Arvanitis; Joseph T Rescinito; Charles R Arnold; Richard G Wilde; Lawrence W Fitzgerald; Robert Zaczek; Paul R Hartig; Scott Grossman; Stephen P Arneric; Paul J Gilligan; Richard E Olson; David W Robertson
Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.
Bioorganic & medicinal chemistry letters 2003;13(1):129-31.
2003: Argyrios G Arvanitis; Joseph T Rescinito; Charles R Arnold; Richard G Wilde; Gary A Cain; Jung-Hui Sun; Jia-Sheng Yan; Christopher A Teleha; Lawrence W Fitzgerald; John F McElroy; Robert Zaczek; Paul R Hartig; Scott Grossman; Stephen P Arneric; Paul J Gilligan; Richard E Olson; David W Robertson
Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.
Bioorganic & medicinal chemistry letters 2003;13(1):125-8.
2001: SP Ho; Lorey K Takahashi; V Livanov; K Spencer; T Lesher; C Maciag; Mark A Smith; K W Rohrbach; Paul R Hartig; Stephen P Arneric
Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.
Brain research. Molecular brain research 2001;89(1-2):29-40.
2000: Dietmar Seiffert; Jodi D Bradley; Cynthia M Rominger; David H Rominger; F Yang; Jere E Meredith; Qian Wang; Arthur H Roach; Lorin A Thompson; Susan M Spitz; Jeffrey N Higaki; Shimoga R Prakash; Andrew P Combs; Robert Copeland; Stephen P Arneric; Paul R Hartig; David W Robertson; Barbara Cordell; Andrew M Stern; Richard E Olson; Robert Zaczek
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors.
The Journal of biological chemistry 2000;275(44):34086-91.
2000: L He; Paul J Gilligan; Robert Zaczek; Lawrence W Fitzgerald; John F McElroy; H S Shen; JA Saye; N H Kalin; S Shelton; D Christ; George L Trainor; Paul R Hartig
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
Journal of medicinal chemistry 2000;43(3):449-56.
2000: Paul J Gilligan; C Baldauf; AJ Cocuzza; DR Chidester; Robert Zaczek; Lawrence W Fitzgerald; John F McElroy; Mark A Smith; H S Shen; JA Saye; D Christ; George L Trainor; David W Robertson; Paul R Hartig
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist.
Bioorganic & medicinal chemistry 2000;8(1):181-9.
2000: Lawrence W Fitzgerald; Timothy C Burn; B S Brown; JP Patterson; M H Corjay; P A Valentine; Jung-Hui Sun; John R Link; I Abbaszade; JM Hollis; Brian L Largent; Paul R Hartig; Gregory F Hollis; P C Meunier; Albert J Robichaud; David W Robertson
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Molecular pharmacology 2000;57(1):75-81.
1999: Lawrence W Fitzgerald; G Iyer; D S Conklin; C M Krause; A Marshall; JP Patterson; D P Tran; G J Jonak; Paul R Hartig
Messenger RNA editing of the human serotonin 5-HT2C receptor.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2 Suppl):82S-90S.
1999: SP Ho; Paul R Hartig
Antisense oligonucleotides for target validation in the CNS.
Current opinion in molecular therapeutics 1999;1(3):336-43.
1999: Lawrence W Fitzgerald; D S Conklin; C M Krause; A P Marshall; JP Patterson; D P Tran; G Iyer; Walter A Kostich; Brian L Largent; Paul R Hartig
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
Journal of neurochemistry 1999;72(5):2127-34.
1998: R Grzanna; J R Dubin; G W Dent; Z Ji; W Zhang; SP Ho; Paul R Hartig
Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects.
Brain research. Molecular brain research 1998;63(1):35-52.